Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ornidazole + sodium chloride is a fixed-dose combination used primarily for the treatment and prevention of anaerobic bacterial and protozoal infections, especially when intravenous administration is required. Ornidazole is a nitroimidazole antibiotic that acts by damaging the DNA of susceptible bacteria and protozoa, leading to cell death. It is effective against conditions such as septicemia, meningitis, peritonitis, post-operative wound infections, postnatal sepsis, septic abortion, endometritis, trichomoniasis, amebiasis, giardiasis, and has also been used in Crohn's disease maintenance therapy. Sodium chloride serves as an electrolyte replenisher in the formulation to maintain fluid balance during infusion[1][2][3][7]. The combination is typically administered intravenously as a sterile solution[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ornidazole + sodium chloride.